Clinical Trials
47 trialsVeliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
VIGOR
European Organisation for Research and Treatment of Cancer - EORTC
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
National Cancer Institute (NCI)
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
TEMOBIC
Assistance Publique Hopitaux De Marseille
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
City of Hope Medical Center
CERTIS1
AstraZeneca
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
PRO-GLIO
Oslo University Hospital
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Masonic Cancer Center, University of Minnesota
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
St. Jude Children's Research Hospital
Investigational Imaging Technique During Brain Surgery
Emory University
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
ERAS801-SARG
Jonsson Comprehensive Cancer Center
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
TUVASTRAT
Grupo Español de Investigación en Neurooncología
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
The Methodist Hospital Research Institute
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
Wake Forest University Health Sciences
AB-218-IIT-201
Melbourne Health
Temporally-modulated Pulsed Radiation Therapy (TMPRT) After Prior EBRT for Recurrent IDH-mutant Gliomas
Washington University School of Medicine
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Servier
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
SIGMA
Nuvation Bio Inc.
rQNestin
Dana-Farber Cancer Institute